Table I.
Levels of ALT, AST, ALP, TC and GGT in the serum of different treatment groups.
| Group | ALT, U/l | AST, U/l | ALP, U/l | TC, mmol/l | GGT, U/l |
|---|---|---|---|---|---|
| NC | 31.1±4.3 | 65.4±10.0 | 128.7±13.9 | 1.5±0.1 | 1.0±0.0 |
| TP | 78.3±13.7a | 300.3±118.2a | 172.0±32.5a | 2.6±0.8a | 1.8±0.9a |
| SLT | 46.0±7.5c | 138.5±24.3c | 164.5±35.2 | 1.9±0.3c | 1.2±0.6 |
| SMT | 42.4±7.0c | 130.9±31.0c | 139.9±31.3b | 1.8±0.2c | 1.1±0.3b |
| SHT | 40.8±7.8c | 105.9±17.6c | 136.0±20.8b | 1.7±0.6c | 1.0±0.3b |
Doses of 50, 100 and 200 mg/kg silymarin were employed in SLT, SMT and SHT groups, respectively. Data are presented as the mean ± standard deviation, n=12.
a
P<0.01 vs. NC group
b
P<0.05
c
P<0.01 vs. TP group. ALT, alanine transaminase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TC, total cholesterol; GGT, γ-glutamyl transferase; NC, normal control; TP, triptolide; SLT, low-dose silymarin treatment; SMT, middle-dose silymarin treatment; SHT, high-dose silymarin treatment.